A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Bipolar DisorderDepression

Interventions

DRUG

PF-04455242

Single dose of up to 30 mg PF-04455242, delivered in capsule.

Trial Locations (3)

Pfizer Investigational Site, New Haven

Pfizer Investigational Site, New Haven

Pfizer Investigational Site, New Haven